Ebola monkeys were treated with one pill and this is the most promising developme for humans.
According to RCO News Agency, According to a new study published on Friday, Ebola monkeys can be treated with only one pill, and these findings can pave the way for more practical and affordable treatmes for humans.
Ebola was first ideified in year 6 and is thought to have come from bats. It is a deadly viral disease that spreads through direct coact with the patie’s body fluids and causes severe bleeding and organs.
Since the prevalence of the disease mainly occurs in southern Saharan Africa, pharmaceutical companies lack financial inceives to develop appropriate treatmes, and the dispersed nature of the prevalence of the disease has made it difficult for clinical tests.
Only one vaccine for the disease is widely confirmed in year 6, and while two iravenous aibodies improve the results, they need to be maiained in costly refrigerators and are difficult to prescribe some of the poorest areas in the world.
Thomas Geisbert, a virgin at the University of Texas Medical Branch in Galoston, which led the new study in Science Advances, says: “We are really trying to provide a more practical option to use, corol and corol the outbreak.”
Gizbert and his colleagues tested an aiviral Obeldesivir drug, which is an iravenous venous Remdesivir form and was originally made to treat Cuvid-1.
Abdulzizir is a “polymerase inhibitor”, meaning it blocks an enzyme that is critical to the virus reproduction.
The researchers coaminated the roseus and synomulgus macakers with a high dose of the Ebola virus type. One day after exposure to the virus, the monkeys received an abdelzizir tablet daily for 5 days, while the other three monkeys as the corol group received no cure and lost their lives.
Abdulzizir protected 2 % of synomulgus macacons and 2 perce of roseus macacons that are biologically closer to humans.
The drug not only removed the virus from the blood of the monkeys treated, but it also created an immune response and helped them produce aibodies, while preveing organs from damage.
Gizbert explained that while the number of monkeys was relatively small, the study was statistically powerful because they were exposed to an extremely high dose of the virus, which was about 5,000 times the deadly dose for humans. This reduced the need for extra corol monkeys and restricted the unnecessary deaths of animals.
The researcher, who has worked on Ebola since the 1980s, says one of the most exciting aspects of Abdulzir was its extensive protection compared to aibody therapies, which only works against the Ebola Zairi species. “This is a big advaage,” says Gizbert.
Giliad Pharmaceutical Company is currely advancing clinical trials to the second phase of Marburg. The virus, one of Ebola’s close relatives.
Gizbert also emphasized the importance of financing by the US National Health Institute.
He said: 5 % of the costs of all these drugs and vaccines made against Ebola and many of these strange pathways and ages are provided by the US governme. I think the general public agree that we need treatmes for Ebola.
The end of the message
(Tagstotranslate) Ebola
